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Elucidating the genetic basis of complex traits and diseases in non-European populations is particularly challenging because USminority
populations have been under-represented in genetic association studies.We developed an empirical Bayes approach named XPEB (cross-
population empirical Bayes), designed to improve the power for mapping complex-trait-associated loci in a minority population by
exploiting information from genome-wide association studies (GWASs) from another ethnic population. Taking as input summary sta-
tistics from two GWASs—a target GWAS from an ethnic minority population of primary interest and an auxiliary base GWAS (such as a
larger GWAS in Europeans)—our XPEB approach reprioritizes SNPs in the target population to compute local false-discovery rates. We
demonstrated, through simulations, that whenever the base GWAS harbors relevant information, XPEB gains efficiency.Moreover, XPEB
has the ability to discard irrelevant auxiliary information, providing a safeguard against inflated false-discovery rates due to genetic het-
erogeneity between populations. Applied to a blood-lipids study in African Americans, XPEBmore than quadrupled the discoveries from
the conventional approach, which used a target GWAS alone, bringing the number of significant loci from 14 to 65. Thus, XPEB offers a
flexible framework for mapping complex traits in minority populations.Introduction
Genome-wide association studies (GWASs) combined with
sequencing have fundamentally transformed the field of
human complex-trait genetics; since 2007, thousands of
loci have been identified for a broad spectrum of traits
and diseases.1 However, the success of GWASs has been pri-
marily confined to populations of European descent.
Minority individuals, such as African-American (AA) and
Hispanic-American (HA) individuals, who together repre-
sent 28% of the US population (US 2010 census), are prom-
inently missing from many studies. For example, the
largest GWAS of plasma lipids (the Global Lipids Genetics
Consortium or GLGC) included over 188,000 individuals
of European ancestry and identified more than 150 loci
associated with lipid traits.2 By comparison, the largest
published discovery GWAS for lipid traits in US minorities
comprised only ~8,000 AA and ~3,500 HAwomen.3 In part
for this reason, minority samples have predominantly
been utilized for replication, generalizability, and/or fine
mapping rather than primary GWAS discovery.4–9
Although several large-scale GWASs dedicated exclusively
to AA and HA populations are underway,10 these studies
are nonetheless underpowered on the basis of the empir-
ical evidence that complex traits and diseases are often
influenced by a myriad of variants, each with moderate
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lenges are likely to be exacerbated amongminority popula-
tions as we move toward sequencing-based studies. As a
result, there is a widening gap in our knowledge about ge-
netic risk factors for complex diseases across racial and
ethnic groups.
Much of the success of GWASs in European populations
owes to the ability to combine cohort-specific summary re-
sults from a large number of studies via meta-analysis tech-
niques. It is therefore reasonable to hypothesize that the
efficiency of complex-trait association studies in minority
populations might be improved when smaller minority
samples are analyzed in conjunction with the much larger
European and European-American cohorts. Indeed, there
is accumulating evidence that, for a variety of complex
traits and diseases, there is substantial overlap in trait-asso-
ciated loci between ethnicities.7,9,12 For plasma lipid
concentration, we previously demonstrated that trait-
influencing loci show excess overlap among AA, HA, and
European-descent (EU) populations and that loci identified
in EU populations explain a disproportionate amount of
the phenotypic variance in both AA and HA popula-
tions.3 Despite such overlap, conventional meta-analysis
approaches—both fixed-effects and random-effects
models—are not appropriate for combining data across
race and ethnicity. These approaches assume that the un-
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or similar, but heterogeneity in genetic architecture be-
tween ethnicities is well documented. A well-known
example is the APOE ε4 allele, which confers considerably
higher risk of Alzheimer disease in Japanese than in AA in-
dividuals.13 Moreover, because European sample sizes are
often much larger than those of minority individuals, the
meta-analysis framework (which weighs individual studies
according to sample size or the inverse of the estimated
variance) preferentially identifies loci showing association
in Europeans while sacrificing power to detect minority-
specific risk loci.
On the basis of these considerations, we propose an
empirical Bayes (EB) approach14,15 designed to elucidate
the genetic architecture of complex traits in a minority
ethnic population while adaptively incorporating GWAS
information from other ethnicities. We reason that the
general relevance of GWAS results across ethnicities is
often unknown a priori and might depend on both the ge-
netic architecture of a specific trait and the evolutionary
relationship between populations; however, it can be
gauged empirically on the basis of the genome-wide
consistency in association evidence. In other words, if
the underlying genetic basis of a trait is similar between
two ethnicities, and the genetic architecture is polygenic,
we would observe greater overlap in loci showing trait asso-
ciation in the two populations than expected by chance.
We show through simulations that our proposed cross-
population empirical Bayes (XPEB) approach behaves
sensibly. When the underlying trait-associated loci largely
coincide, XPEB effectively combines the two populations
and approximates the power of a fixed-effects meta-anal-
ysis; at the other extreme, when the genetic bases are
entirely population specific, XPEB only uses the popula-
tion of interest (referred to as the target population).
When genetic architecture partially overlaps, XPEB outper-
forms fixed-effects and random-effects meta-analyses, as
well as the approach of considering only the target
population.Material and Methods
Data and Model
Consider a situation in which GWASs have been conducted for a
trait in a target (e.g., AA) population and a base (e.g., EU) popula-
tion and in which SNP-level summary statistics are available in
both target and base populations atMmarkers. The goal is to iden-
tify risk variants in the target population.Wemake no assumption
with regard to the genetic similarity between the target and base
populations but require that the target GWAS and base GWAS be
performed on non-overlapping individuals.
Let Sm and S
0
m be the test statistics (to be specified) of markerm in
the target and base populations, respectively. Within each popula-
tion, the distribution of the test statistic is modeled as a mixture
with J þ 1 components, of which the first component represents
the null distribution of the test statistics at markers not associated
with the trait, and the remaining components represent the alter-
native distributions of the test statistics at trait-associated markers.The AmWe introduce an unobserved Bernoulli random variable, Dm, at
each marker m, such that Dm ¼ 1 with a probability of p1 and in-
dicates that the test statistic observed in the target population is
drawn from a non-null component. Thus, in the target popula-
tion, the test statistics have a density of
gðsÞ ¼ ð1 p1Þg0ðsÞ þ p1
XJ
j¼1pjgjðsÞ; (Equation 1)
where p1 represents the proportion of non-null markers and p ¼
(p1, /pJ), ð
PJ
j¼1pj ¼ 1Þ represents the relative proportions of
non-null SNPs that are associated with the phenotype at varying
degrees; gj(s) (j ¼ 1,.,J) are densities corresponding to the non-
null components, which are described briefly in the next section
and in detail in Appendix A. For notational simplicity, we denote
the weighted sums of the non-null components in Equation 1 as
~gðsÞ. To formulate the corresponding density in the base popula-
tion, we assume that the distributions of allelic effects are similar
between populations. In other words, on average, the relative frac-
tion of loci with strong andweak effects—measured by the propor-
tion of phenotypic variance explained by each locus—is similar
between populations, even though any given locus is not neces-
sarily shared. Therefore, we let p be shared between target and
base populations and modify gj(s) to account for the differential
target and base GWAS sample sizes (Appendix A). We allow the
overall contribution of the non-null component, p1 and p
0
1, to
differ between the target and base populations because the num-
ber of ‘‘detectable’’ loci in a GWAS depends on the sample size.
It follows that the density of S0m differs from Equation 1 in the
null proportion, p01, and the shape of the non-null components,
g 0j ðsÞ:
g 0ðsÞ ¼ 1 p01g0ðsÞ þ p01XJj¼1pjg 0j ðsÞ: (Equation 2)
Additionally, let D0m denote the unobserved random variable that
determines whether the test statistic in the base population is
drawn from the null or the non-null component.
The key insight underlying the proposed approach is that, at
each marker m, the random variables (Dm and D
0
m) are not inde-
pendent if the genetic architecture overlaps between the target
and base populations, and the degree of overlap can be estimated
on the basis of the empirical genome-wide joint distribution of the
observed GWAS statistics (Sm and S
0
m) across all markers. Specif-
ically, we model the conditional probabilities, PðDm ¼ 1jD0m ¼ 0Þ
and PðDm ¼ 1jD0m ¼ 1Þ, as constant across the genome and denote
these two parameters as k0 and k1, respectively. Assuming that Sm
and S0m are independent given Dm and D
0
m; respectively, the likeli-
hood of observing a test statistic sm is
gðsmÞ ¼
X
a˛f0;1g
X
b˛f0;1g
P

D0m ¼ a j S0m

P

Dm¼b jD0m ¼ a

PðSm jDm ¼ bÞ
¼ 1 v0m½ð1 k0Þg0ðsmÞ þ k0~gðsmÞ
þ v0m½ð1 k1Þg0ðsmÞ þ k1~gðsmÞ;
(Equation 3)
where n0m ¼ PðD0m ¼ 1
S0mÞ, and the overall likelihood of S (under
linkage equilibrium), is simply
likðSÞ ¼
Y
m
gðsmÞ: (Equation 4)
In Equation 3, 1 n0m has the interpretation of the local false-dis-
covery rate (locfdr) for testing the statistical association between a
SNP and the trait in the base population.16 Maximizing the likeli-
hood of Equation 4 provides estimates for themodel parameters inerican Journal of Human Genetics 96, 740–752, May 7, 2015 741
Equation 3; these parameters are used for computing the posterior
probability, PðDm ¼ 0jSm; S0mÞ, which will be used as the cross-
population locfdr of genotype-trait association in the target
population.
Implementation of XPEB
The model described above is applicable to any GWAS summary
statistics. Two natural choices are t statistics and p values, which
differ only in that t statistics, but not p values, inform the direction
of association. However, t statistics are not always available, and
even when they are, merging two lists of t statistics can be prone
to error because of the ambiguity in the designation of the refer-
ence alleles. In contrast, p values are the most widely shared sum-
mary statistics and do not rely on consistent coding of the refer-
ence alleles; therefore, we choose to base our implementation on
p values. More precisely, in the likelihood of Equation 3, we use
c21 statistics for S and S
0, which can be derived from either p values
or t statistics through a quantile transformation. It is then reason-
able to use a c21 distribution as the null component (g0) in the
mixture densities of Equations 1 and 2 and to use a mixture of
non-central c21 distributions to represent the non-null compo-
nents. We introduce non-null basis functions gj(s) (with j ¼
1,.,J and J ¼25), each of which is itself a continuous mixture of
non-central c21 distributions. These basis functions are fixed a pri-
ori with masses concentrating at different values (Figure S1),
reflecting the expectation that allelic effects under a polygenic ar-
chitecture might span a broad spectrum, as measured by the pro-
portions of phenotypic variance explained.11 Each basis function
in the base and target populations is scaled to reflect the unequal
sample sizes between the target and base GWASs. Details on the
formulation of these basis functions are described in Appendix
A. We have experimented with using J ¼ 50 in simulations and
found negligible differences in performance. To estimate the
model parameters, we developed an EB approach that proceeds
in two stages, which are described next. The first stage decon-
volves the mixture density in Equations 1 and 2 by estimating
the mixture proportions, and the second stage estimates parame-
ters k0 and k1 by maximizing the likelihood, lik(S), of Equation 4.
The first stage estimates the mixture proportions (p1, p
0
1, and p)
in Equations 1 and 2 by assuming that the trait-influencing loci are
independently distributed within the target and base populations.
One way to estimate these parameters is to maximize the marginal
likelihood via the EM algorithm.17 However, theoretical studies18
and our own simulations have found that mixture proportions
estimated this way can be undesirably sensitive when the non-
null probabilities in target or base populations are close to 0;
such a situation can arise either because the trait is affected by
just a few loci or because the signal in the GWAS is weak as a result
of small sample sizes. As an alternative, we implemented a hierar-
chical Bayesian model, implemented via a Markov Chain Monte
Carlo (MCMC) algorithm, to explore multiple plausible deconvo-
lutions (see Appendix A). We use the posterior mean as the esti-
mated mixture proportions. Once the mixture proportions are
estimated, we can compute n0m for each marker by substituting
the estimated parameters as follows:
n0m ¼ P

D0m ¼ 1 j S0m
 ¼ bp01PJj¼1bpjg 0j ðsÞ
1 bp01g0ðsÞ þ bp01PJj¼1bpjg 0j ðsÞ:
(Equation 5)
Analogously, the target-only posterior probability of association
is defined as nm ¼ PðDm ¼ 1jSmÞ. The goal of the second stage of742 The American Journal of Human Genetics 96, 740–752, May 7, 2the algorithm is to adaptively integrate information from the
target and base populations. We use an EB approach to estimate
parameters k0 and k1, which maximizes the likelihood function
of Equation 4 while being subject to the constraints
0%k0%k1%2 < 1. In the implementation, we set 2 ¼ 0:9 and
express a belief that the genetic architectures in two popula-
tions are seldom identical; this restriction improves numerical sta-
bility without substantial loss of efficiency. Finally, the XPEB
locfdr for the SNP association in the target population, um, is
computed as
um ¼ P

Dm ¼ 0 j Sm; S0m
 ¼ 1 y0mð1 bk0Þ þ y0mð1 bk1Þg0ðsmÞbg ðsmÞ ;
(Equation 6)
where bg ðsmÞ is the likelihood of observing a test statistic sm,
defined in Equation 3 and evaluated by the substitution of esti-
mated parameter values. Note that the cross-population posterior
estimates reduce to a one-population model in the special case
that k0 ¼ k1; in other words, when XPEB does not detect evidence
of overlapping genetic architecture, results in the base GWAS are
ignored.
The model and implementation described thus far assume that
markers are independent; that is, there is no linkage disequilib-
rium (LD) between SNPs. LD affects two aspects of the procedure.
First, during estimation of the mixture proportions, the presence
of LD can lead to an over-estimation of non-null proportions, p1
and p01. To overcome this problem, we introduce an LD-trimming
step and estimate these parameters in two iterations (see Appendix
A). A second effect of LD is that differential LD patterns between
the target and base populations can lead to an under-estimate of
k1, as we explain in the Results and demonstrate through simula-
tions. However, such a downward bias in k1 leads to slightly
conservative estimates of locfdr but does not inflate false-positive
estimates. Hence, the uncorrected bk1, estimated on full data, is
used in all subsequent simulation and data analyses.Simulations
We used two sets of simulation experiments to evaluate the perfor-
mance of the proposed approach. The first set of experiments
directly simulated test statistics on the basis of theoretically
computed non-centrality parameters; this approach did not simu-
late individual genotypes and assumed that all markers were inde-
pendent (i.e., no LD). The simulation proceeded in three stages.
The first stagemodeled the genetic architectures of the trait, which
is assumed to have an additive genetic architecture specified by the
total heritability (h2) and the number of causative variants in each
population (K), of which a fraction of d loci are shared between the
target and base populations. We emphasize that although both pa-
rameters d and k1 measure the degree of overlap, d is a simulation
parameter and is allowed to range between K/M (independence)
and 1 (complete overlap), whereas k1 is a model parameter with
the constraints specified by XPEB. Under such a trait model, stage
two simulated the allelic effect and additive variance attributable
to each causal locus. At target-specific or base-specific trait-associ-
ated loci, the allelic effects, l, were sampled independently from a
standard normal distribution. At a shared trait-associated locus,
the allelic effects in target and base populations were sampled
from a bivariate normal distribution, N

0
0
	
;

1 r
r 1
	

, where
r ¼ 0.7. The phenotypic variance attributable to locus m can be
computed as xm ¼ Cl2mfmð1 fmÞ, where f denotes the allele015
frequency and C is a normalizing constant such that the total ad-
ditive variance matches the pre-specified heritability. The allele
frequencies atM simulatedmarkers were sampled without replace-
ment from the 1000 Genomes Project variants (phase 1 release
v.3).19 EU populations were used for the base GWAS, and popula-
tions of African ancestry were used for the target GWAS; minor
allele frequencies (MAFs) greater than 1% were required in both
populations. Given xm and under the assumption that xm is small,
the GWAS test statistic (on a Z scale) at this causative SNP was
sampled from a normal distribution with mean xm
ﬃﬃﬃ
n
p
(where n is
the sample size) and variance 1. The remaining M  K SNPs were
assumed to not be associated with the trait, and the test statistics
were sampled from a standard normal distribution.
The simulated dataset—consisting of a list of Z statistics in each
of the target and base populations—was analyzed via four strate-
gies: (1) p values in the target population alone (target only), (2)
locfdr estimated by the proposed EB approach combining target
and base populations (XPEB), (3) fixed-effectsmeta-analysis imple-
mented in PLINK (meta-FE),20 and (4) random-effects meta-anal-
ysis implemented in METASOFT (meta-RE, corresponding to the
‘‘PVALUE_RE2’’ in METASOFT output), which has been demon-
strated to achieve higher power than the classic random-effect
meta-analysis method.21 For meta-analysis, the SEs for the esti-
mated allelic effects from a linear regression model are given by
s2m ¼ ð1 xmÞ=½2fmð1 fmÞðn 2Þ. Hence, the estimated allelic
effects were computed as Zmsm. XPEB declares a positive finding
by using a locfdr threshold, whereas the other three methods use
a p value threshold. Decisions from each of these strategies were
compared against the simulation gold standard, defined as the
set of risk loci in the target population, and the numbers of false-
positive and false-negative discoveries were recorded. We note
that the stringency of a p-value-based testing procedure is not
directly comparable to that of a procedure based on false-discovery
rate (FDR).22 Furthermore, although a p value of 53 108 is widely
adopted as a significance criterion in GWASs, studies using FDR-
based approaches do not always use the same significance levels.
With these considerations in mind, we compared the numbers
of true loci discovered while adjusting the p value or locfdr thresh-
olds such that each of the four tests had the same number of false-
positive discoveries. We then varied the calibration number of
false-positive discoveries so that the relative performance of these
methods could be evaluated over a range of statistical stringencies.
We emphasize, however, that in analyzing real data, the signifi-
cance criterion should be fixed prior to the analysis.
The approach described above is computationally efficient and
allowed us to explore the effects of different aspects of model pa-
rameters. However, it is difficult to incorporate a realistic pattern
of LD under this framework; therefore, we adopted a complemen-
tary approach that directly simulates individual-level genotype
data and traits. Specifically, we used YRI (Yoruba in Ibadan,
Nigeria) and CEU (Utah residents with ancestry from northern
and western Europe from the CEPH collection) genotypes from
HapMap phase 3 as the prototypes for the target and base popu-
lations, respectively.23 We used HAPGEN2, which introduces mu-
tation and recombination between haplotypes, to simulate ten
CEU (base) cohorts and one YRI (target) cohort, each of which
included 10,000 individuals.24 We restricted all simulations and
analyses to ~727,348 SNPs, which are on the Illumina Human
1M array and have a MAF greater than 1% in both the simulated
target and base populations. Instead of simulating haplotypes
that span an entire chromosome, we generated independent win-
dows of 25 linked SNPs (i.e., SNPs within a window inherit the LDThe Ampattern in the HapMap sample, whereas SNPs that reside in
different windows are unlinked). We emphasize that these 25-
SNP windows (spanning a median of 79 kb) captured the essential
and realistic features of LD in the population.25 The motivation
for simulating independent windows was to achieve unambigu-
ous definition of false-positive and true-positive findings: a win-
dow in which at least one SNP is deemed statistically significant
was considered a true-positive finding if the window harbored a
trait-associated SNP; otherwise, this window was considered a
false positive no matter how many SNPs were falsely rejected
within the window. The trait-associated loci and the allelic effects
were specified similarly as in the previous set of simulation exper-
iments, but there was an additional constraint of at most one
causative SNP per window. The positions of causal SNPs were
identical across all ten CEU-derived cohorts, and the allelic effects
had a correlation of 0.9 between the cohorts. A fraction of d of the
causal SNPs coincided between the CEU-derived and the YRI-
derived populations, and cross-ethnic correlations in allelic effects
were 0.7 at the overlapping causal SNPs. The individual geno-
types, causative SNPs, and allelic effects were then used as input
in the program GCTA (Genome-wide Complex Trait Analysis),
which simulates quantitative or binary disease traits with the
pre-specified heritability.26 To reduce computational and data-
storage burden, we simulated the genotypes of the 11 cohorts
once and used these genotype data to simulate multiple sets of
quantitative and case-control traits; a similar strategy was used
and discussed in Wu et al.27 For each trait, a GWAS was performed
with PLINK for each cohort separately. The four procedures
described in the previous simulations of independent loci—target
only, XPEB, meta-FE, and meta-RE—were compared. For XPEB,
the ten CEU cohorts were meta-analyzed first (with PLINK’s
fixed-effects model), and the meta-analysis summary statistics
were used as the base GWAS. For the fixed-effects and random-
effects meta-analyses, the estimated allelic effects and the SEs
for the estimated allelic effects from the 11 individual cohorts
were provided to PLINK and METASOFT, allowing for better esti-
mates of inter-study variability.
Analysis of Lipid Traits
To apply our method to real data, we analyzed high-density lipo-
protein (HDL) cholesterol, low-density lipoprotein (LDL) choles-
terol, and triglyceride (TG) levels. For the target GWAS, we used
results from the Women’s Health Initiative SNP Health Associa-
tion Resource (WHI-SHARe), which consists of 8,153 post-meno-
pausal AA women. Details of the cohort characteristics, pheno-
type transformation, and GWAS analyses were reported
previously.3 For the base GWAS, we used summary-level statistics
reported by GLGC,28 a meta-analysis of ~100,000 individuals pri-
marily of European descent. As negative controls, we also used
European GWAS results in height29 and body mass index
(BMI)30 for a base GWAS. Because the sample sizes of the target
GWAS and base GWAS were used for constructing the non-null
basis, gj(s) and g
0
j ðsÞ, respectively, SNPs with excessive missing ob-
servations were removed (see footnotes ‘‘a’’ and ‘‘e’’ in Table 2).
For SNPs whose summary statistics were available in the target
GWAS but missing in the base GWAS, nm was computed analo-
gously as in Equation 5, and 1  nm was reported as the locfdr.
Regions harboring SNPs with locfdr < 0.05 were considered statis-
tically significant and reported. As validation, we compared the
allelic effects at trait-associated loci identified by XPEB to the cor-
responding allelic effects estimated in an independent cohort of
7,138 AA participants from the NHLBI Candidate-Geneerican Journal of Human Genetics 96, 740–752, May 7, 2015 743
Figure 1. Decision Boundary for XPEB versus That of the Con-
ventional Single-Population Approach
S (x axis) and S0 (y axis) represent the chi-square test statistics in
the target and base GWASs, respectively. The dashed magenta ver-
tical line corresponds to the conventional approach, which uses
the target GWAS alone and a genome-wide significance of p ¼
5 3 108. Solid curves delineate the decision boundaries con-
structed by XPEB, in which the overlap in genetic architecture
(k1) varies; the yellow line labeled k1 ¼ k0 corresponds to the
case where trait-associated loci are independently distributed in
the base and target populations. All other model parameter values
are taken from the estimates obtained from the LDL data.Association Resource (CARe) Study and in a cohort of 3,587 HA
participants from WHI-SHARe.Results
The distinction between XPEB and the conventional sin-
gle-population approach is qualitatively illustrated in
Figure 1. The conventional practice rejects the null hy-
pothesis of no association at a SNP if and only if it exceeds
a pre-specified threshold (i.e., p < 5 3 108, dashed
magenta line in Figure 1) in the target GWAS and does
not depend on results in the base population. In contrast,
the XPEB approach considers the combined evidence of as-
sociation in both target and base populations (solid lines in
Figure 1). The negative slope of the decision boundaries
supports the intuition that the burden of proof in the
target population can be reduced by the evidence of asso-
ciation in the base population. As a result, the minimal
target evidence for rejecting the null hypothesis can
be substantially weaker for XPEB. The slope depends
on the simulation parameter d, which represents the de-
gree of overlap in the genetic architecture underlying the
trait in the two populations and is empirically estimated
as bk1 on the basis of genome-wide test statistics. The
greater the overlap, the more influence the base GWAS ex-
erts. When little overlap is detected, the XPEB reduces to a
target-only approach with a vertical decision boundary
that is independent of the base GWAS (yellow line in
Figure 1). Regardless of the estimated overlap, target-spe-
cific trait-associated variants can be detected with a suffi-
ciently strong statistic in the target GWAS alone, in which744 The American Journal of Human Genetics 96, 740–752, May 7, 2case the test statistic in the base population is effectively
ignored, and XPEB coincides with the conventional
p value decision. In contrast, a SNP cannot be declared
significant on the basis of the strength of evidence in the
base population alone as long as bk1 < 1, indicated by
the vertical gap between the y axis and each decision
boundary (Figure 1). This asymmetric feature emphasizes
our primary goal of identifying relevant trait variants
in the target population and distinguishes XPEB from
meta-analysis. Additional Figure 1 features, which are not
essential to the understanding of XPEB, are discussed in
Appendix A.
Simulations with Independent SNPs
The output of XPEB is an estimated locfdr for each
SNP. We recommend rejecting all SNPs with a locfdr fall-
ing below a pre-specified threshold (e.g., locfdr < 0.05);
alternatively, one can successively reject SNPs with
increasing locfdrs until the average locfdr of the rejected
set, denoted as the Fdr, reaches a pre-specified threshold
(e.g., Fdr < 0.05). Table 1 summarizes the number of
true and false discoveries under various simulation set-
tings and significance criteria. As expected, the largest
locfdr of the rejected SNP set is a conservative estimate
of the realized FDR (rFDR). In contrast, the average
locfdr of the rejected set tracks well with the rFDR
except for d ¼ 1, in which case the average locfdr of
the rejected set is also conservative in comparison to the
rFDR. Additional simulations have verified that the
conservatism is due to the constraint of bk1%0:9; the esti-
mated locfdr becomes less conservative when the bound
increases.
Next, we compared the performance of XPEB with
that of three common approaches: (1) p values in the
target population alone (target only), (2) a standard
fixed-effects meta-analysis (meta-FE), and (3) a random-
effects meta-analysis method combining target and
base GWASs (meta-RE).21 SNPs are ranked according to
increasing locfdrs under the XPEB approach and accord-
ing to increasing p values under the single-population
and meta-analysis approaches. Figure 2 compares the
number of false-positive rejections that a method makes
in order to correctly discover a given number of truly
causative (true-positive) variants. Each curve can be
thought of as a partial receiver operating characteristic;
hence, methods characterized by a greater area under
the curve (AUC) are preferred over ones with a lower
AUC. As expected, the target-only approach was robust
against genetic heterogeneity, whereas the random-
effects meta-analysis had the greatest power when the
genetic architectures were identical across populations
(Figure 2). XPEB combined the strengths of both
methods.
In a situation where the trait variants are independently
distributed in target and base populations, the target-only
and XPEB approaches have the desired behavior of using
the target GWAS alone and discarding the information015
Table 1. True-Positive and False-Positive Counts at Different locfdr Significance Levels in Simulations of Independent Loci
Statistic
Genetic
Architecture
Significance Level
0.01 0.05 0.1
TP FP rFDR TP FP rFDR TP FP rFDR
locfdra null targetb 0 0 ND 0 0 ND 0 0.02 ND
d ¼ 0.001 66.4 0.04 6.0 3 104 82.9 0.40 4.7 3 103 91.2 0.91 9.9 3 103
d ¼ 0.25 81.8 0.06 7.2 3 104 103.4 0.59 5.6 3 103 115.1 1.43 1.2 3 102
d ¼ 0.5 110.2 0.13 1.2 3 103 141.7 1.15 8.0 3 103 160.6 2.81 1.7 3 102
d ¼ 0.75 152.7 0.27 1.7 3 103 202.9 1.99 9.4 3 103 234.8 5.80 2.3 3 102
d ¼ 1 208.1 0.03 1.4 3 104 285.2 0.30 1.1 3 103 340.1 0.83 2.4 3 103
Fdrc null target 0 0 ND 0 0 ND 0 0.03 ND
d ¼ 0.001 87.5 0.73 8.3 3 103 109.5 5.33 4.6 3 102 122.0 13.00 9.6 3 102
d ¼ 0.25 109.2 0.93 8.4 3 103 139.6 7.49 5.1 3 102 157.5 17.93 1.0 3 101
d ¼ 0.5 149.3 1.68 1.1 3 102 196.2 11.41 5.5 3 102 224.9 27.52 1.1 3 101
d ¼ 0.75 211.2 2.72 1.2 3 102 290.0 20.09 6.2 3 102 345.9 50.53 1.2 3 101
d ¼ 1 295.6 0.41 1.4 3 103 438.5 2.57 5.8 3 103 554.5 13.07 2.3 3 102
Abbreviations are as follows: TP, number of true-positive findings; FP, number of false-positive findings; rFDR, realized FDR or the proportion of false-positive SNPs
among the SNPs deemed significant; Fdr, average locfdr calculated as the average locfdr of the marker set with equal or lower locfdr; ND, not defined.
aNumber of TP and FP findings and rFDR at different XPEB locfdr significance thresholds. These are averages of 100 simulations for each genetic-architecture
degree of overlap (d); simulation parameters are the same as in Figure 2.
bSimulations for the null case were of 1,000 causal loci in the base GWAS and no causal loci in the target GWAS.
cNumber of TP and FP findings and rFDR for the same simulations at different average locfdr (Fdr) thresholds.from the base population (Figure 2D). Both meta-FE and
meta-RE analyses, in contrast, are strongly driven by the
larger GWAS in the base population; consequently, these
methods essentially rediscover trait-associated variants in
the base population (instead of discovering those in the
target population) and incur an unacceptably inflated
false-positive rate. At the opposite extreme, if the trait-
associated variants of the target and base populations
were known to completely overlap, then a meta-analysis
would be the sensible procedure. However, even in such
a situation, XPEB achieved an efficiency similar to that of
the meta-FE andmeta-RE analyses, unless a very high spec-
ificity was imposed (e.g., less than ten false positives; inset
in Figure 2A). In this setting, the target-only approach suf-
fered a substantial loss of power for ignoring the informa-
tion from the base population. For traits with partially
overlapping causative variants, the XPEB outperformed
the target-only, meta-FE, and meta-RE approaches (Figures
2B and 2C). Simulations varying other factors, such as the
sample sizes of the GWAS and the heritability of the trait,
suggest that XPEB has more power than the target-only
and meta-analysis approaches across a broad range of set-
tings (Figure S2). The numbers of false positives and true
positives incurred by the four methods at a conventional
threshold of p < 5 3 108 or locfdr < 0.05 are compared
in Table S1. Overall, XPEB, which achieves competitive
or superior performance under broad scenarios without
requiring a priori assumptions of the degree of overlap in
genetic architecture, offers a practical strategy for
analyzing a variety of traits.The AmSimulations with LD
The relative performance of XPEB and the target-only,
meta-FE, and meta-RE approaches followed similar pat-
terns in the presence of LD. As explained in the Material
and Methods, in this simulation the decision was made
for a window harboring multiple SNPs rather than a single
SNP. Figure S3 and Table S2 compare power characteristics
of the four methods: target only, meta-FE, meta-RE, and
XPEB. As with the previous set of experiments, XPEB out-
performed the other three methods when the trait-associ-
ated loci partially overlapped; it performed competitively
with the best of the other three methods when trait-associ-
ated loci were either entirely overlapping or independently
distributed in the target and base populations (Figure S3).
We also simulated binary disease traits by using GCTA;
the relative efficiency was similar when the target and
base p values were derived from case-control analyses.
On the basis of a previously developed argument,31 the
estimated locfdr produced by XPEB controls for the frac-
tion of falsely rejected SNPs but not for the fraction of
falsely rejected windows. However, if we retain only the
minimum locfdr in each rejected window, the maximum
of these minimum locfdrs remains a conservative estimate
for the falsely discovered windows, and the average of
these minimum locfdrs provides a good approximation
of the rFDR (Table S3).
Interestingly, whereas k1, the parameter measuring the
degree of overlap in genetic architecture, could be esti-
mated with little bias in the absence of LD, bk1 was substan-
tially under-estimated in the presence of LD (Figure 3).erican Journal of Human Genetics 96, 740–752, May 7, 2015 745
Figure 2. Partial Receiver Operating
Characteristic under Independent Simula-
tions with Varying Degrees of Overlap
Number of true-positive (y axis) and false-
positive (x axis) discoveries according to
four methods—XPEB, p value in the target
GWAS alone (target only), p value from a
fixed-effects meta-analysis of base and
target GWASs (meta-FE), and p value
from a random-effects meta-analysis of
base and target GWASs (meta-RE produced
by METASOFT)—for d ¼ 1 (A), 0.75 (B), 0.5
(C), and 0.001 (D). Each simulated dataset
consisted of 106 independent markers, of
which 1,000 causal SNPs explained 70%
of the phenotypic variance; the base
GWAS had a sample size of 105 individuals,
and the target GWAS included 104 individ-
uals. Each curve is based on the average of
100 simulations. The inset in (A) indicates
that meta-analysis (meta-FE and meta-RE)
performed better than XPEB at very low
false-positive counts (<10) when d ¼ 1;
otherwise, XPEB performed as well as or
better than other methods considered.This occurs because SNPs in strong LDwith a causal variant
will appear to come from the non-null components. Even
if the causal variants are identical in the base and target
populations, these ‘‘shoulder’’ SNPs might not coincide
because of incongruent local LD patterns in the base and
target populations. This discrepancy would be considered
evidence of genetic heterogeneity, causing under-estima-
tion of the degree of overlap and leading to a loss of power.
Plasma Lipid Concentration in AAWomen
Previously, we performed genome-wide association ana-
lyses of lipid concentrations in AA and HA women from
WHI-SHARe.3 A total of 13, 15, and 5 SNPs representing
6, 5, and 3 loci, respectively, were associated with HDL,
LDL, and TG, respectively. We re-analyzed this dataset by
using the XPEB approach and the summary statistics
from the GLGC as the base GWAS.28 On a 2.66-GHz Intel
Xeon processor, each analysis took an average of 20 min.
For all three traits, XPEB estimated very high overlap in ge-
netic architecture between EU and AA individuals: bk1
achieved themaximal allowed value. At locfdr< 0.05, a to-
tal of 177, 140, and 133 SNPs at 29, 19, and 17 loci, respec-
tively, were discovered for HDL, LDL, and TG, respectively.
Without using the base GWAS, we estimated nm ¼ P(Dm ¼
1jSm) in a parallel fashion (as described in Equation 5), and
found three, four, and two loci reaching locfdr < 0.05
for HDL, LDL, and TG, respectively. This indicates that746 The American Journal of Human Genetics 96, 740–752, May 7, 2015the increased loci detected by XPEB
were not due to the locfdr’s being
less conservative than the p-value-
based genome-wide-significant crite-
rion. The estimated FDR, computed
as the average of the minimum locfdr
across all significant loci, was 0.012.The 65 loci identified by XPEB included 13 of 14 loci pre-
viously identified on the basis of the p values in WHI-
SHARe AA individuals alone; the single exception was a
chromosome 21 HDL-associated locus (p ¼ 2.26 3 108),
which has not been replicated in another cohort3 (Table
S4 and Figure S4). Figure S5 illustrates the relationship be-
tween the p value in the WHI-SHARe AA analysis (target
GWAS) and the XPEB locfdr that incorporates the associa-
tion strength in the base GWAS.
We sought to validate the loci discovered by XPEB in two
datasets: a cohort of 7,138 AA individuals fromCARe32 and
a cohort of 3,587 HA individuals fromWHI-SHARe.3 Over-
all, there was strong agreement in the sign of the estimated
effects: 56 of 62 loci agreed in direction between WHI-
SHARe AA and CARe AA individuals (two-sided binomial
test, p¼ 2.973 1011), and 57 of 65 loci agreed in direction
between WHI-SHARe AA and HA individuals (two-sided
binomial test, p ¼ 3.16 3 1010; Table S4). Furthermore,
significant loci identified by XPEB in WHI-SHARe AA indi-
viduals were enriched with small p values in WHI-SHARe
HA and CARe AA individuals and showed correlated allelic
effects (Figures S6 and S7). Therefore, it is reasonable to
expect that a majority of the loci detected by XPEB in
WHI-SHARe AA individuals will be replicated in much
larger AA cohorts. Of note, two loci for each of the HDL,
LDL, and TG traits did not reach p ¼ 5 3 108 for the cor-
responding lipid trait in either the target GWAS3 or the
Figure 3. XPEB-Estimated Overlap
Parameter Values versus the True Values
(A) The XPEB-estimated overlap parameter
(bk1, y axis) corresponds well to the true
overlap parameters used in the simulation
(d, x axis) in simulations of independent
loci. The red bar indicates the median ofbk1 based on 100 simulations; the simula-
tion setting is identical to that described
in the legend of Figure 2.
(B) In the presence of LD, XPEB under-esti-
mated the degree of overlap. The red bar
is the median of bk1 based on 20 simula-
tions. Each simulation included ~727,000
markers, of which 1,000 SNPs were causal
and together explained 70% of the pheno-
typic variance. Genotypes were simulated
to represent ten cohorts in the base population and one cohort in the target population (each cohort consists of 104 individuals). LD
in the base and target populations was simulated to resemble that of HapMap CEU and YRI, respectively.base GWAS,28 suggesting that trans-ethnic analysis has the
potential to augment our understanding of complex traits
in all populations.Cross-phenotype XPEB Analysis
One situation researchers face is that some studies use
related but not identical phenotypes. For example, is it
appropriate to use a study of LDL in EU populations as
the base GWAS to learn about HDL in AA populations?
To address this question, we applied XPEB to pairs of traits
for which we had GWAS summary statistics in AA (target)
and EU (base) populations. The estimated degree of overlap
is shown in Table 2. For each lipid trait, when thematching
trait was used as the base GWAS, the estimated k1 was uni-
formly high. When biologically related traits were
analyzed together, (e.g., LDL in the base GWAS and HDL
in the target GWAS), this parameter dropped sharply, sug-
gesting pleiotropic loci but only a partially overlapping ge-
netic basis. When seemingly unrelated traits were used,
(e.g., height29 or BMI30 in the base GWAS and LDL in the
target GWAS), the overlap parameters were essentially
zero. Thus, XPEB provides a safeguard against combining
incompatible phenotypes by ignoring the base GWAS.Discussion
This research was motivated by the observation that the ef-
ficiency of genetic association studies and the accuracy of
using genetic variants for predicting disease risk—whether
by genotyping or by sequencing—depends critically on
sample size.33 Given the challenges in establishing well-
phenotyped minority cohorts, and the empirical findings
that many trait-associated loci mapped in minority popu-
lations are actually shared across ethnicities, we reasoned
that a method that borrows information from populations
with large cohorts could accelerate complex-trait genetic
research in minority populations. However, the precise
degree to which we can borrow information across popula-
tions depends on the similarity in genetic architecture be-The Amtween populations, which is usually unknown and is both
trait and population specific.
We aimed to remove the often subjective decision of
selecting and meta-analyzing compatible GWASs by devel-
oping XPEB, a principled approach that adaptively
integrates results from related GWASs. XPEB is computa-
tionally efficient and uses summary statistics that are
commonly available. Simulation studies suggest that
when the underlying trait-associated loci partially overlap
between populations, XPEB outperforms both target-only
and meta-analysis approaches (Figures 2B, 2C, S3B, and
S3C). When trait-associated loci are independently distrib-
uted within the base and target populations, XPEB resem-
bles the target-only approach, and both of these methods
outperform meta-analysis (Figures 2D and S3D). In cases
where all trait-associated loci are shared between the target
and base populations, XPEB andmeta-analysis outperform
the target-only approach. Although meta-analysis might
achieve higher power than XPEB if the allelic effects are
highly correlated, the difference is generally modest (Fig-
ures 2A and S3A).
XPEB differs from meta-analysis approaches in imple-
mentation and interpretation, and they serve different
goals.34 An implicit assumption meta-analysis makes is
that there is an underlying population; the observed test
statistics in a given GWAS represent a realization from a
sub-population. The fixed-effects meta-analysis approach
assumes a constant allelic effect among all studies, whereas
the random-effects meta-analysis approach allows the
allelic effects to vary around an overall population value.
A recently developed trans-ethnic meta-analysis approach,
MANTRA, forms clusters among multiple GWASs; subse-
quently, a fixed-effects approach is used to combine studies
that represent genetically similar populations within a
cluster, and a random-effects approach is used to combine
studies across clusters.35 We wish to emphasize that
although XPEB makes use of multi-ethnic GWAS results,
it is not a trans-ethnic meta-analysis approach because its
goal is to identify trait-associated loci that are relevant in
the target population. To define this distinction moreerican Journal of Human Genetics 96, 740–752, May 7, 2015 747
Table 2. Overlap and Number of Significant Loci Estimated by XPEB for the Lipid Phenotypes in the WHI-SHARe AA Cohort
Base GWAS
Target GWAS
WHI-SHARe HDL (na ¼ 7,913) WHI-SHARe LDL (n ¼ 7,857) WHI-SHARe TG (n ¼ 7,914)
Overlapb Locic Overlap Loci Overlap Loci
Noned NA 3 NA 4 NA 2
European HDL (ne ¼ 99,720) 0.90 29 0.25 4 0.66 12
European LDL (n ¼ 95,290) 0.25 7 0.90 19 0.33 3
European TG (n ¼ 96,420) 0.68 11 0.33 5 0.90 17
European BMI (n ¼ 123,800) 0.26 3 0.14 3 0.004 2
European height (n ¼ 133,700) 0.10 3 0.04 3 0.12 2
NA stands for not applicable.
aMedian sample sizes in target GWASs across markers. SNPs with fewer than 7,000 non-missing observations were removed, leaving 852,739 SNPs for all lipid
phenotypes.
bFor each specified target and base GWAS combination, the XPEB estimates of the degree of overlap (k1) are reported.
cNumber of loci with locfdr < 0.05. A significant locus is defined as a set of SNPs with locfdr < 0.05 and a distance between significant SNPs < 1 Mb.
dNumber of loci with locfdr < 0.05 on the basis of WHI-SHARe AA individuals alone.
eMedian sample sizes in the base GWAS across markers. For BMI and height, SNPs with fewer than 100,000 non-missing observations were removed; for HDL, LDL,
and TG, SNPs with fewer than 80,000 were removed. This left 621,117, 615,089, 616,513, 627,441, and 631,843 SNPs overlapping with the target GWAS SNPs
for the HDL, LDL, TG, BMI, and height phenotypes, respectively.precisely, denote the set of true trait-associated loci in the
target population as T and the set of true trait-associated
loci in the base population as B. Fixed-effects, random-ef-
fects, and trans-ethnic meta-analysis approaches such as
METASOFTandMANTRA aim to detectTWB. The interpre-
tation of a significant finding is that the SNP is associated
with the trait in some meta-population represented by
the conglomeration of all studies (Figure S8). In contrast,
XPEB focuses on a specific population designated by the
target GWAS, and its goal is to identify set T. Information
from the base GWAS is auxiliary and is only allowed to in-
fluence the locfdr if it empirically shows compatibility
with the target GWAS. Importantly, loci in set B but not
in set T (base-specific traits) are considered false positives
under XPEB, but they are considered true positives in
trans-ethnic meta-analysis.
The practical difference between meta-analysis and
XPEB can be clearly appreciated in a situation where the
sample size of the base GWAS far outnumbers that of the
target GWAS and the risk loci only partially overlap, a real-
istic situation in the analysis of a target GWAS from a
minority group and a base GWAS performed in EU popula-
tions. In such a situation, meta-analysis essentially re-iden-
tifies trait-associated loci in the base population (B); a
fraction of these loci are not shared between populations
and are therefore false positives with respect to the target
population. As a result, meta-analysis incurs a high FDR
even at stringent statistical significance. This is not the
case for XPEB, as indicated by the decision boundary in
Figure 1. A SNP association will not be declared significant
without association evidence in the target population, no
matter how strong the association is in the base popula-
tion; however, with sufficiently strong evidence, target-
specific loci (TyB) can be detected without support in
the base population.748 The American Journal of Human Genetics 96, 740–752, May 7, 2Although our primary motivation was to integrate
GWASs from heterogeneous populations, XPEB is also
applicable when related traits might provide supportive in-
formation. Recent studies examining multiple phenotypes
found evidence of pleitropic effects for groups of traits
including cancers, psychiatric disorders, and metabolic
syndromes.36–38 When can GWASs from related traits be
combined? Rather thanmaking a subjective decision about
the appropriateness of combining such studies, XPEB of-
fers an objective approach to selectively borrow informa-
tion from traits whose genetic basis partially overlaps
that of the target trait. When we used XPEB to determine
whether HDL loci are relevant for understanding the ge-
netic architecture of LDL, we found that HDL indeed pro-
vides information about LDL but that the influence is
weaker than that from an LDL study (Table 2). Therefore,
we envision XPEB as broadly applicable, for example, for
determining whether a GWAS of mammographic density
informs risk loci for breast cancer.
The intuition of up-weighing a set of candidate SNPs on
the basis of external information has been explored in the
context of genetic association studies, but most studies as-
sume either that the weighing scheme can be fixed a priori
or that the set of candidate SNPs are pre-defined. For
example, to weigh association results by linkage evidence,
it is often reasonable to assume that the linkage peaks and
association signals largely overlap; therefore, a pre-deter-
mined weighing scheme might work well.39 Recently,
several Bayesian and EB approaches have been developed
for prioritizing GWAS results.40–44 Most of these methods
aim to incorporate biological information and are based
on the belief that truly causal genetic variants are enriched
in some pathways or share specific functional annotation.
Whereaspathwayandannotation informationare assumed
to be known without error (a gene is either in a pathway or015
not), the same is not true for the association evidence in the
base GWAS that XPEB tries to integrate. Whether a variant
influences the trait in the base population is not directly
observed in anyGWASof finite sample size; even the largest
GWAS to date is underpowered to detect the many variants
with small effects. Hence, one contribution of the XPEB
approach is to simultaneously determine the weighing
scheme and account for the imperfect information in the
base GWAS. A second statistical contribution is an
improved deconvolution algorithm for themixture density
in Equations 1 and 2: this algorithm achieves greater nu-
merical stability over commonly used approaches, such as
the expectation-maximization (EM) algorithm. Estimating
the components of the mixture density is particularly chal-
lenging when one component dominates; in our situation,
we expect that an overwhelming majority of SNPs are not
associated with the trait. Consistent with the theoretical
investigation,18 our simulation indicates that the EM algo-
rithm yields numerically unstable estimates when the non-
null proportions are low. The MCMC-based algorithm we
implement in XPEB ameliorates this problem by consid-
ering multiple plausible deconvolutions. This part of the
algorithm is stand-alone and could be incorporated as a
module in other types ofmixture-deconvolution problems.
XPEB could be enhanced in several directions. The likeli-
hood model in Equation 3 could be extended so that
multiple base GWASs could be adaptively integrated simul-
taneously. Another area of improvement would be to bet-
ter model the LD between markers. Our simulation results
suggest that ignoring LD between markers leads to an
underestimation of the degree of overlap and thus reduces
the efficiency of the method (Figure 3). Likewise, XPEB
does not explicitly model allelic heterogeneity: when a
large fraction of overlapping trait-associated loci harbor
population-specific trait variants, the degree of overlap
can also be underestimated (data not shown). Hence,
XPEB errs on the conservative side, and a model that prop-
erly accounts for LD structure and allelic heterogeneity
might be able to borrow information from the base
GWAS more aggressively.
Although XPEB improves our ability to map complex
traits in minority populations by using a GWAS from a
distantly related population with large cohorts, studies
that focus on minority populations remain critical.
Borrowing information from related populations cannot
be a substitute for minority-specific studies. Increased sam-
ple size in the target population will improve the efficiency
of XPEB in threeways. First, the power of target-specific loci
can only be detected through an increased sample size in
the target population. Second, for trait-associated loci that
are shared between target and base populations, increased
sample size in either population will improve the overall
power; however, increasing the sample size in the target
population is likely to bring greater marginal gain, because
the base GWAS most likely outnumbers the target GWAS
already. Finally, as the degree of overlap (k1) is estimated
on the basis of the consistency in the occurrence of putativeThe Amtrait-associated loci in the target and base populations,
increasing the sample size of the target population will
improve the accuracy of the overlap parameter by bringing
more true trait-associated loci into a detectable range. We
also note that, as demonstrated in the lipid-trait example
(Table S4), integrating GWAS results across populations by
usingXPEB can potentially uncover truly novel trait-associ-
ated loci that are not significant in either the target or the
base GWAS. We advocate that minority-specific cohorts
continue to be developed, but minority-specific GWASs
should be analyzed in conjunction with related studies
across ethnicities. Ultimately, by using sufficiently large
sample sizes and borrowing information across ethnicities,
we have the opportunity to gain a comprehensive under-
standing of the genetic architecture of complex traits by
assembling information across populations.Appendix A
The Null and Non-null Components of the Mixture
Densities
According to the notation used in the Material and
Methods, let sj and s
0
j be the observed test statistics for
marker j in the target and base populations, respectively.
The marginal distributions of S and S’, modeled as mixture
densities, are displayed as Equations 1 and 2 in the Mate-
rial and Methods, respectively. In both of these mixture
densities, the null distribution, g0, is modeled as a c
2
1
random variable, regardless of the GWAS sample size.
The test statistic at a marker, m, associated with the trait
follows a non-central c21 distribution with non-centrality
parameters x2mn, where x
2
m measures the proportion of vari-
ance explained by the variant and n is the sample size. We
assume that the marginal distributions of x are shared be-
tween target and base populations, but the non-centrality
parameters are adjusted to account for different sample
sizes.
We now describe the individual non-null components,
gj, of Equation 1. The formulation of g
0
j in Equation 2 is
completely analogous. We adopted a hierarchical model
in which gj has the density of a c
2
1 random variable with
a random non-centrality parameter. Let dbetaðq; a; bÞ
denote the density at q of a beta random variable with
parameters a and b. Let F(x;h) be the cumulative density
function (CDF) at x of a c21 random variable with a non-
centrality parameter of h. The CDF of gj takes the form
GjðxÞ ¼
Z 1
0
F
 
x;n
exp

cq2  1
expðc  1Þ
!
dbetaðq; j; J þ 1 jÞdq:
In the implementation of XPEB, we let J ¼ 25, c ¼ 9,
and n be the sample size in the target GWAS. The dis-
tribution of the non-centrality parameter, hðqÞ ¼
n expðcq2  1Þ=expðc  1Þ, is designed so that h ranges
from 0 to n, and the mean of h increases with j. If we as-
sume that the strongest trait-associated locus explains noerican Journal of Human Genetics 96, 740–752, May 7, 2015 749
more than half of the total phenotypic variation—an
assumption that holds for virtually all non-Mendelian
traits—the maximum non-centrality parameter value for
S at sample size n is n. Figure S1 displays a series of CDFs,
Gj, (j ¼ 0,/,25), for n ¼ 100,000.
Estimating Parameters in Equations 1 and 2
We next describe a MCMC algorithm for computing the
posterior mean estimates of p1, p
0
1, and p. For this step,
we treat the observed statistics, sj and s
0
j, as independent
draws from the mixture density in Equations 1 and 2 and
seek the parameters that maximize the pseudo-likelihood
function,
L ¼
Y
i
gðsiÞg

s0i

: (Equation A1)
The priors of the parameters are specified as follows: p1
and p01 are assumed to be independent draws from a
density
fmðxÞ ¼ ð1 gðmÞÞxgðmÞ1ð0 < x%1Þ;
where g(m) ¼ (1  2m)/(1  m) and m ¼ 106. The density
function, fm(x), is designed to reflect a conservative belief
that only a small fraction of the genome affects the
trait: the density has an expectation of m, features a
spike at 0, and decays rapidly near 0. The vector p ¼
(p1,/,pJ) is modeled as a draw from a Dirichlet of order J,
Dir(a,/, a), where a is a hyper-parameter with a uniform
prior of U(0,1).
The posterior distributions of the parameters are
computed by MCMC via the Metropolis-Hastings algo-
rithm.45 Two kinds of moves are proposed: (1) random
perturbation of the p1, p
0
1, or a parameter and (2) perturba-
tion of the relative non-null components, (pj1, pj2), subject
to the constraints that 0% pj%1 for all j and
P
pj ¼ 1before
andafter themove. The lattermoves,whichhave the effects
of shiftingmass between non-null components, gj1 and gj2,
either choose a random pair of distinct coordinates (j1,j2)
uniformly from 1 to J or shift mass between adjacent coor-
dinates (j, j þ 1). Proposals that perturb p1, p01, or a occur
with a probability of 1/15 each;mass shift between random
pairs of coordinates and mass shift between adjacent coor-
dinates are each proposed with a probability of 2/5. All
simulation and data analyses presented in the Results are
based on 106 MCMC steps. In subsequent estimation of k0
and k1, as well as the calculation of locfdr, the posterior
mean of p1, p
0
1, and pj from this MCMC step was used.
Evaluating the likelihood in Equation A1 is computa-
tionally intensive because gj(sm) does not have a closed an-
alytic form. To reduce computational burden, we adopted a
trick46 in which the likelihood function is not evaluated
with the raw s and s0 values. Instead, data are binned
into 500 intervals, resulting in counts ci and c
0
i for bins Bi
and B0i, respectively. Let Mij denote the mass assigned to
bin Bi under distribution Gj, and define M
0
ij analogously
in the base GWAS. These Mij and M
0
ij are pre-computed by
numerical integration and stored in two matrices. The750 The American Journal of Human Genetics 96, 740–752, May 7, 2discretized L is then L ¼QiðmiÞciðm0iÞc0i , where mi ¼
ð1 p1ÞMi0 þ p1
PJ
j¼1pjMij and m
0
i is defined analogously.
LD Trimming
A two-iteration parameter-estimation procedure, which in-
cludes an LD-trimming step, is introduced to correct for
the biased p1, p
0
1, and p estimates (due to LD) in the
mixture densities. In iteration 1, the two-step algorithm
described in the Material and Methods is applied to the
full data without consideration of LD; next, any regions
showing suggestive evidence of association, defined as
maxðnm; v0m;1 umÞ > 0:5 for some marker m in the re-
gion, are trimmed by removal of all markers except the
one that achieves the minimum um in the region. In the
simulation experiments, which generated haplotypes of
25-SNP windows, the underlying window boundary was
used for defining regions; in the real-data analysis, SNPs
showing suggestive evidence of association and within
200 kb of each other were merged into one region, given
that most observed GWAS peaks span less than that range.
Finally, in iteration 2, p1, p
0
1, p, and k0 are re-estimated with
the trimmed dataset, and the locfdr is computed with
Equation 6 in the Material and Methods for all SNPs.
Additional Explanations of Figure 1
Figure 1 displays the contours of locfdr ¼ 0.05 for various
values of k1 while fixing k0; p1;p
0
1, and other simulation
parameters at known values. The conventional genome-
wide significance threshold of 5 3 108 is plotted to aid
qualitative comparison, but we wish to make a conceptual
distinction: although the conventional p-value-based sig-
nificance criterion controls the family-wise error rate,
XPEB controls the FDR;47 the stringencies of these signifi-
cance criteria are not directly comparable.22 Furthermore,
the particular threshold value of XPEB depends on the
number of detectable true trait-associated loci, which in
turn depends onmodel parameters k0, k1, p1, and pj. There-
fore, the x intercept of XPEB decision boundaries can fall
higher or lower than that of the p-value-based criterion.
In Figure 1, we set p1 ¼ p01 ¼ 0:001, the true simulation
values, and used the estimated bp based on theWHI-SHARe
LDL data.
Perhaps more curious is the observation that the XPEB
decision boundaries can cross each other when k1 varies:
the x intercept of the decision boundary for k1 ¼ 0.9 is
greater than the corresponding x intercept for k1 ¼ k0 ¼
0.001. In fact, this is sensible for the following reasons:
when k1 [ k0, a majority of SNPs showing association
evidence in the target GWAS are likely to show strong asso-
ciation in the base GWAS as well. Hence, the lack of evi-
dence of association at a SNP in the base GWAS is Bayesian
evidence against the hypothesis that this SNP is associated
with the trait in the target GWAS. Stronger evidence of
association is required in the target GWAS in order to
compensate for this contrary evidence. Of course, such
comparison assumes that all other model parameters are
held equal.015
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